Hepatocellular Carcinoma Non-Resectable
Conditions
Brief summary
This study is to assess the efficacy and the safety of hepatic arterial infusion of cisplatin and 5-fluorouracil (HAIC) in advanced HCC patients stratified by biomarker expression predicting therapeutic response.
Detailed description
Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and 5-fluorouracil has been used in advanced HCC. However, cisplatin or 5-fluorouracil acts on cells without tumor selectivity. Therefore, to improve the tumor selectivity and effectiveness of HAIC, molecular subtyping-based stratification strategies should be considered. In this study, patients who have progressed or intolerance to sorafenib with non-metastatic HCC in TNM stage III-IVA and ECOG PS 0 or 1, Child-Pugh class A will be enrolled. 96 patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times. The primary objective is to determine overall response rate, where benefit is defined as complete or partial response according to mRECIST V1.1. Secondary endpoints include time to progression, progression free survival. The biopsy tissue will be subjected to real time reverse transcriptase polymerase chain reaction for quantification of gene expression levels. Patients will be categorized into two groups according to gene expression results, and then AUC value of ROC curve analysis will be evaluated as an exploratory endpoint to assess predictive performance of biomarker for therapeutic response of HAIC.
Interventions
DRUGcisplatin and 5-fluorouracil
Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
Sponsors
CbsBioscience
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* over 20 years old * Patients with advanced hepatocellular carcinoma who have progressed or intolerance to Sorafenib * Patients with advanced hepatocellular carcinoma who cannot be treated with surgery, transplantation, RFA, or TACE. * TNM stage III/IV (including intrahepatic single or multiple tumors without extrahepatic metastasis regardless of lymph node metastasis) * ECOG performance status of 0 or 1 * Liver function status of Child-Pugh Class A or B * more than 3 months of life expectancy * serum creatinine \<1.5 mg/dL * aminotransferase \<5 times the upper limit of normal * absolute neutrophil count \>1,500 cells/lL * platelet count \>75,000/lL * hemoglobin \>10 g/dL
Exclusion criteria
* patients with extrahepatic tumors * Patients requiring combined treatment with chemotherapy, radiotherapy, TACE, RFA, or others * Patients in any severe and/or uncontrolled medical conditions * patients with history of allergic response to CT contrast media * patients who participated as subjects in other interventional clinical studies (as of the date of visit) within 60 days before drug administration * Any person deemed inappropriate by reason of the investigator for other reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective tumor response | Approximately 6 months | Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by radiological review |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free-survival | Approximately 24 months |
| Time-to-Progression | Approximately 24 months |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory endpoint: Diagnostic performance of biomarkers | Through study completion, an average of 3 months | Patients will be categorized according to the result of biomarker expression and then AUC value of ROC curve analysis will be evaluated as an exploratory endpoint to assess predictive performance of biomarkers for therapeutic response of drugs. |
Countries
South Korea
Contacts
Primary ContactJin Young Park
Outcome results
None listed